Bright-field microscopy for HER2 gene assessment not just dish-ful thinking?

American Journal of Clinical Pathology

Volumn 139, Issue 2, 2013, Pages 137-139

  Clark, Beth Z ^a   Bhargava, Rohit ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN;

ANEUPLOIDY; BREAST CARCINOMA; BRIGHT FIELD MICROSCOPY; CANCER CHEMOTHERAPY; CHROMOSOME 17; CLINICAL DECISION MAKING; DNA PROBE; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; HEALTH CARE QUALITY; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST TUMOR; FEMALE; IN SITU HYBRIDIZATION; METABOLISM; METHODOLOGY; NOTE; PAGET NIPPLE DISEASE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2;

EID: 84875081800     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP26LRFURXTOBO     Document Type: Editorial

References (14)

1. Lal P, Salazar PA, Hudis CA, et al. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: A single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol. 2004;121:631-636.
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
3. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
4. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: An assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005;11:6598-6607.
5. Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002;20:3095-3105.
6. Bhargava R, Lal P, Chen B. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: Does it measure up to fluorescence in situ hybridization? Am J Clin Pathol. 2005;123:237-243.
7. Isola J, Tanner M, Forsyth A, et al. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res. 2004;10:4793-4798.
8. Mayr D, Heim S, Weyrauch K, et al. Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: Comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Histopathology. 2009;55:716-723.
9. Bartlett JM, Campbell FM, Ibrahim M, et al. A UK NEQAS ISH multicenter ring study using the Ventana HER2 dualcolor ISH assay. Am J Clin Pathol. 2011;135:157-162.
10. Bartlett JM, Campbell FM, Ibrahim M, et al. Chromogenic in situ hybridization: A multicenter study comparing silver in situ hybridization with FISH. Am J Clin Pathol. 2009;132:514-520.
11. Brugmann A, Lelkaitis G, Nielsen S, et al. Testing HER2 in breast cancer: A comparative study on BRISH, FISH, and IHC. Appl Immunohistochem Mol Morphol. 2011;19:203-211.
12. Mansfield AS, Sukov WR, Eckel-Passow JE, et al. Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer. Am J Clin Pathol. 2013;139:144-150.
13. Perez EA, Reinholz MM, Hillman DW, et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol. 2010;28:4307-4315.
14. Ross JS. Human epidermal growth factor receptor 2 testing in 2010: Does chromosome 17 centromere copy number make any difference? J Clin Oncol. 2010;28:4293-4295.